Subtype
Neuroblastoma
CI-CAN-00003408Explore in graph →
137 active trials3 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003408Explore in graph →
Clinical trials
616 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT06684639 |
| A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma |
| recruiting |
| Early Phase 1 |
| 30 |
| The General Hospital of Western Theater CommandOTHER |
| 1 |
| Dec 20, 2024 |
| clinicaltrials |
| NCT05826158 | 18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma | recruiting | N/A | 25 | Rigshospitalet, DenmarkOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06574698 | Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma | recruiting | — | 64 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06296732 | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification(ANLAP-R) | recruiting | — | 200 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05069220 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | recruiting | Early Phase 1 | 150 | Peking Union Medical College HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06255210 | Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)(ESICON) | recruiting | Phase 2 | 25 | Hongmeng YuOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04253015 | A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta | recruiting | — | 125 | RECORDATI GROUPINDUSTRY | 7 | Feb 7, 2024 | clinicaltrials |
| NCT06071897 | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma | recruiting | Phase 3 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06047535 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | not yet recruiting | Phase 4 | 62 | SciClone PharmaceuticalsINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT05931055 | The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer | not yet recruiting | — | 1,000 | Peking Union Medical College HospitalOTHER | 0 | Jul 5, 2023 | clinicaltrials |
| NCT05303727 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | not yet recruiting | Phase 2 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT01704716 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | recruiting | Phase 3 | 3,300 | St. Anna KinderkrebsforschungOTHER | 20 | Oct 23, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jan 30, 2025source: clinicaltrials